< 1 minute read
Mar. 14, 2023

Emraclidine: a Selective Positive Allosteric Modulator of the Cholinergic M4 Muscarinic Receptor

Cerevel/Pfizer M4 positive allosteric modulator

oral, QD M4 PAM Ph. II for schizophrenia discovery not disclosed emraclidine (CVL-231) Cerevel Therapeutics, Cambridge, MA; Pfizer, New York, NY

drughunter.com
Drug Hunter Team

Emraclidine (CVL-231) is a selective positive allosteric modulator (PAM) of the cholinergic M4 muscarinic receptor and is the only selective M4 PAM in clinical development. The molecule has shown promising early results in schizophrenia with several Ph. II trials enrolling and is intended to be developed for Alzheimer’s Disease psychosis as [...]

Loading...

twitterlinkedinemail

Other molecules you may be interested in